TrialThe lancet. HIV2026

Fixed-dose combination bictegravir-emtricitabine-tenofovir alafenamide twice-daily for treatment of HIV during rifampicin-based tuberculosis treatment (INSIGHT Study): a phase 2b, open-label, randomised non-comparative trial.

Anushka Naidoo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.